Due to the anti-inflammatory and immunosuppressive properties of KYN, pharmacological agents capable of, depending on the need, inhibiting or potentiating expression or activation of IDO1 have the potential to be used in treating various intestinal diseases, such as colitis or inflammatory bowel disease (Figure 3) [149,150]. The gene discussed is IDO1; the disease is colitis.